Liraglutide (Victoza/Saxenda)
GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and chronic weight management (Saxenda, 3.0 mg). Albumin-bound with half-life of ~13 hours, dosed once daily. Enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces appetite.
Projected serum levels — 1.8 mg, once daily
Maintenance schedule: 1.8 mg once daily (subcutaneous).
Loading schedule: 2.8 mg on day 1, then 1.8 mg once daily — reaching therapeutic levels sooner.
Modeled steady state after ~2 days: peak ≈ 1.7 mg, trough ≈ 0.92 mg body load. Population-based estimate over 15 days for a 1.8 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Peptide
- Route modeled
- Subcutaneous
- Model confidence
- inferred
- Half-life
- 13 h
- Common dose
- 1.8 mg
- Suggested maximum
- 3 mg/day
- Reference dose range
- 0.90–3 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 1.8 mg sc — Cmax 0.14 mg/L at 9 h
Documented interactions
-
danger
Levothyroxine (Synthroid) + Liraglutide (Victoza/Saxenda)
Liraglutide (Victoza/Saxenda) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…
-
danger
Tacrolimus (Prograf) + Liraglutide (Victoza/Saxenda)
Liraglutide (Victoza/Saxenda) may displace Tacrolimus (Prograf) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…
-
danger
Warfarin (Coumadin) + Liraglutide (Victoza/Saxenda)
Liraglutide (Victoza/Saxenda) may displace Warfarin (Coumadin) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…
-
warning
Apigenin + Liraglutide (Victoza/Saxenda)
Apigenin may displace Liraglutide (Victoza/Saxenda) from plasma protein binding sites, transiently raising free drug concentration.
-
warning
Aripiprazole (Abilify) + Liraglutide (Victoza/Saxenda)
Liraglutide (Victoza/Saxenda) may displace Aripiprazole (Abilify) from plasma protein binding sites, transiently raising free drug concentration.
-
warning
Armour Thyroid (Desiccated Thyroid Extract) + Liraglutide (Victoza/Saxenda)
Liraglutide (Victoza/Saxenda) may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.
Serum checks 143 modeled interaction pairings for liraglutide (victoza/saxenda) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Comprehensive pharmacokinetic review establishing liraglutide elimination half-life of 13 hours, 55% absolute bioavailability, and >98% albumin binding supporting once-daily dosing.
-
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity)
Pivotal SCALE trial showing liraglutide 3.0 mg daily produced 8.0% mean weight loss vs 2.6% with placebo over 56 weeks in adults with obesity.
-
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)
Landmark cardiovascular outcomes trial demonstrating liraglutide reduced the rate of first occurrence of major adverse cardiovascular events by 13% versus placebo.
3 published studies referenced in the app, each with a plain-language summary.